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Background: Since the introduction of tyrosine kinase inhibitors (TKIs) into combination chemotherapy regimens,
the majority of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
patients have achieved complete remission (CR). However, without allogeneic hematopoietic stem cell
transplantation (HSCT), long-term outcomes in adults remain unsatisfactory. Indeed, haploidentical HSCT has
become a common treatment for adult patients who lack an HLA-matched donor, though limited data are
available on the efficacy of haploidentical HSCT in Ph+ ALL patients.
Methods: We analyzed the clinical outcomes of 82 Ph+ ALL patients who underwent haploidentical HSCT (n = 47) or
HLA-matched HSCT (n = 35). Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was
performed to assess BCR-ABL expression. All of the patients were treated with an imatinib-based regimen before
undergoing HSCT. Imatinib treatment was resumed in the patients’ posttransplantation following detection of BCR-ABL
transcripts.
Results: All of the patients achieved neutrophil and platelet engraftment, with the exception of five patients who died
prior to engraftment. Haploidentical HSCT was associated with higher incidences of acute graft-versus-host disease
(GVHD) (51.1 vs. 25.7 %, p < 0.05) and chronic GVHD (48.9 vs. 25.7 %, p< 0.05) compared with HLA-matched HSCT, but
there was no difference in the incidence of either grades III–IV acute GVHD or extensive chronic GVHD. The incidence of
cytomegalovirus (CMV) infection was significantly higher in the patients treated with haploidentical HSCT than in those
treated with HLA-matched HSCT (38.3 vs. 14.3 %, p< 0.05). Haploidentical HSCT was associated with a significantly lower
relapse rate compared with HLA-matched HSCT (44.8 vs. 19.1 %, p< 0.05). There were no differences in non-relapse
mortality (NRM), leukemia-free survival (LFS), or overall survival (OS) between the patients who received HLA-matched
HSCT and those who underwent haploidentical HSCT.
Conclusions: Our data indicate that the incidence of NRM after HSCT is similar between the patients who receive
HLA-matched donor cells and those who receive haploidentical donor cells and that haploidentical HSCT reduces
the relapse rate. Haploidentical HSCT represents an encouraging treatment option for Ph+ ALL patients who lack
a suitable HLA-matched donor.* Correspondence: zhangxxi@sina.com
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Approximately 25–30 % of adults and 3 % of children with
acute lymphoblastic leukemia (ALL) express the onco-
genic BCR-ABL protein, which results from a 9;22
chromosomal translocation known as the Philadelphia
(Ph) chromosome [1]. Ph-positive ALL (Ph+ ALL) is a
high-risk subset of ALL that is associated with a lower
probability of complete remission (CR) than Ph-negative
ALL (Ph− ALL) and that has an extremely poor prognosis
[2]. Most studies have found that Ph+ ALL patients have a
median survival time of 6–12 months [3, 4]. Although the
introduction of tyrosine kinase inhibitors (TKIs) into the
standard combination chemotherapy regimens for newly
diagnosed Ph+ ALL allows over 95 % of patients to
achieve CR [5, 6], Ph+ ALL remains an unfavorable prog-
nostic subgroup with an unacceptably high relapse rate. In
the UKALLXII/ECOG2993 trial, the addition of imatinib
to the chemotherapeutic cocktail in the absence of mye-
loablative allogeneic hematopoietic stem cell transplant-
ation (allo-HSCT) did not result in a significant survival
benefit [7]. Allo-HSCT during the first CR (CR1) remains
the optimal curative treatment for Ph+ ALL to date [3].
The most therapeutically favorable treatment for Ph+ ALL
is allo-HSCT from an HLA-identical sibling donor, but ap-
proximately 70 % of patients lack a suitable sibling donor
[8]. In China, matched unrelated donors [9] are found for
only 20 % of patients who lack a suitable sibling donor,
and umbilical cord blood units are not always suitable for
adult transplantation because they contain insufficient
numbers of cells. However, nearly all patients have at least
one HLA-haploidentical matched family member. Recent
comparative studies have shown that acute leukemia pa-
tients who receive either haplotransplantation or HLA-
matched transplantation have similar outcomes [10, 11],
but the efficacy and safety of haplotransplantation in Ph+
ALL patients have not been examined. Our current study
compares the outcomes of patients who have been diag-
nosed with Ph+ ALL and treated with HSCT using cells
from either haploidentical donors or matched donors.Materials and methods
Patients
We analyzed the clinical data of 82 patients with Ph+ ALL
who underwent either HLA-matched HSCT or haploiden-
tical HSCT at one of five hospitals in southwest China be-
tween July 2007 and April 2011. The diagnosis of Ph+ ALL
was based on the diagnostic criteria of the World Health
Organization (WHO). The BCR-ABL fusion gene was de-
tected by real-time quantitative polymerase chain reaction
(PCR). The study was reviewed and approved by the ethics
committees of the participating institutions. All of the pa-
tients included in this study provided informed consent in
accordance with the Declaration of Helsinki.Conditioning regimen and imatinib therapy
The patients undergoing HLA-matched HSCT were condi-
tioned with 9.0–10.5 Gy total-body irradiation (TBI) on
days −5 and −4 and 60 mg/kg/day intravenous cyclophos-
phamide (CY) on days −3 and −2. The patients undergoing
haploidentical HSCT were conditioned with 9.0–10.5 Gy
TBI on days −7 and −6, 6 g/m2/day intravenous arabinosyl-
cytosine (Ara-C) on days −5 to −3, 45 mg/kg/day intraven-
ous CY on days −3 to −2, and 2.5 mg/kg/day intravenous
anti-thymocyte globulin (ATG) (Sanofi, SangStat, Lyon,
France) on days −5 to −2.
All of the patients received imatinib prior to trans-
plantation. Imatinib was administered posttransplanta-
tion only if BCR-ABL transcripts were detectable by
real-time quantitative PCR and if the patients could tol-
erate oral imatinib without developing gut graft-versus-
host disease (GVHD) or life-threatening infection.
Donors, stem cell mobilization, and stem cell collection
Peripheral blood (PB) and bone marrow (BM) cells were
collected from the donors using standard mobilization
protocols. Granulocyte colony stimulating factor (G-CSF)
(5 μg/kg/day; Filgrastim, Kirin Pharma Co., Ltd., Japan)
was administered to the donors for 5–6 days to mobilize
stem cells in the BM (G-BM) and PB (G-PB). Starting on
the fifth day of G-CSF administration (day 1), G-PB cells
were harvested by large-volume leukapheresis using a
Fenwal CS3000 apparatus (Fenwal, Deerfield, IL, USA). If
the number of mononuclear cells (MNCs) or CD34+ cells
harvested was not sufficient for HLA-matched HSCT,
additional G-PB cells were harvested on day 2. On day 2,
G-BM cells were harvested for haploidentical HSCT. The
goal was to collect at least 4 × 108 MNCs and 2 × 106
CD34+ cells per kilogram of the recipient’s body weight.
GVHD prophylaxis and management
The patients who received HLA-matched HSCT were
treated posttransplantation with mycophenolate mofetil
(MMF), cyclosporin A (CsA), and methotrexate (MTX)
[12]. A total of 500 mg (15 mg/kg for pediatric patients)
of MMF (Roche Pharmaceutical, Ltd., Switzerland) were
administered orally every 12 h from day 1 until day 30.
Continuous intravenous CsA (2.5 mg/kg/day) was ad-
ministered starting on day −1 and was continued until
the patient was able to tolerate oral medication. Next,
2.5 mg/kg CsA was administered orally twice per day to
achieve a blood concentration of 200–300 ng/mL for
90 days. The dose of CsA was then gradually reduced. In
total, 15 mg/m2 MTX was administered intravenously
on day 1, and 10 mg/m2 MTX was administered on days
3 and 6. The patients who received haploidentical HSCT
were treated posttransplantation with ATG, MMF, CsA,
and MTX. In addition to the standard treatment with
ATG, MMF was administered from day −7 until day 90.
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on day −7, and the dose was increased to 2.5 mg/kg/day
on day −1, and it was replaced with oral medication. Over
the next 150–180 days, the dose of CsA was gradually re-
duced. A total of 15 mg/m2 MTX were administered on
day 1, and 10 mg/m2 MTX were administered on days 3,
6, and 11.
The patients who developed GVHD were treated with
1–2 mg/kg/day methylprednisolone or prednisolone and
2.5 mg/kg/day CsA. The patients who developed steroid-
refractory GVHD were treated with second-line immuno-
suppressive therapies, such as MMF, tacrolimus (FK506,
Astellas, Japan), or anti-CD25 monoclonal antibodies
(Novartis Pharma, Ltd., Switzerland).
Evaluation and definitions
The degree of hematopoietic chimerism was determined
using a PCR-based assay that detects short tandem re-
peats in DNA. Full donor chimerism was defined by the
detection of 95 % or more donor cells in whole-blood
samples [13]. Disease relapse was defined on the basis of
morphology, detection of the BCR-ABL fusion gene, or
evidence of leukemic cells in either the BM or other
extramedullary organs. Leukemia-free survival (LFS) was
defined as the shortest interval between HSCT and re-
lapse or non-relapse mortality (NRM) or the last follow-
up. Transplantation-related toxicity (TRT) was evaluated
using standard criteria established by the National Cancer
Institute (NCIC; www.ecog.org/general/ctc). Damage to
the patients’ organs that was due to either GVHD or in-
fectious complications was excluded from this analysis.
Statistical analysis
Overall survival (OS) and LFS were estimated using the
Kaplan-Meier method. GVHD, disease relapse, and NRM
rates were estimated using cumulative incidence analysis.
For GVHD, death without an event was a competing risk.
NRM and relapse were considered to be mutually compet-
ing risks. Univariate analysis was conducted using Cox re-
gression. Multivariate analysis was performed using the
Cox proportional regression model. SPSS version 16.0
statistical software was used for Kaplan-Meier, univariate,
and multiple regression analyses. R software version 2.15.2
was used for competing risk analysis for GVHD, NRM,
and relapse.
Results
Characteristics of patients and donors
The demographic characteristics and relevant transplant-
ation data for the patients who were included in this study
are shown in Table 1. The characteristics of the patients
who received either HLA-matched HSCT or haploidentical
HSCT were not significantly different. Many of the patients
achieved CR and were BCR-ABL fusion gene-negative afterseveral cycles of chemotherapy because all of the patients
received imatinib in combination with standard chemo-
therapy prior to transplantation. In the HLA-matched
HSCT group, seven patients were BCR-ABL fusion gene-
positive, and the BCR-ABL gene expression rate before
HSCT was 2.95 %. In the haploidentical HSCT group, ten
patients were BCR-ABL fusion gene-positive, and the
BCR-ABL gene expression rate before HSCT was
2.42 %. All 17 patients were BCR-ABL fusion gene-
negative posttransplantation.
Engraftment and chimerism
The numbers of MNCs and CD34+ cells are shown in
Table 2. Excluding the two patients who received HLA-
matched HSCT and the three patients who received haploi-
dentical HSCT who died prior to engraftment, 77 patients
achieved engraftment of both neutrophils and platelets.
The median time to achieve an absolute neutrophil count
(ANC) >0.5 × 109 cells/L were 14 days (range 9–54 days) in
the patients who received HLA-matched HSCTand 15 days
(range 10–22 days) in those who received haploidentical
HSCT (p = 0.225). The median time until platelet en-
graftment totaled >20 × 109 cells/L were 14 days
(range 9–210 days) in the patients who received HLA-
matched HSCT and 15 days (range 10–33 days) in
those who received haploidentical HSCT (p = 0.134).
All of the surviving patients had complete donor chimerism
by 60 days after transplantation.
GVHD and toxicity
The cumulative incidence of acute GVHD (aGVHD)
among the patients who received haploidentical HSCT
(24 patients, 51.1 %; 95 % (CI), 35.8–64.4 %) was sig-
nificantly higher than that among those who received
HLA-matched HSCT (9 patients, 25.7 %; 95 % (CI),
12.6–41.1 %) (p = 0.026, Fig. 1a). There was no differ-
ence in the incidence of grades III–IV aGVHD be-
tween the patients who received HLA-matched HSCT
(11.4 %; 95 % (CI), 3.5–24.5 %) and those who received
haploidentical HSCT (17.0 %; 95 % (CI), 7.8–29.1 %)
(p = 0.504, Fig. 1b). The 2-year cumulative incidence
of chronic GVHD (cGVHD) was higher among the pa-
tients who received haploidentical HSCT (23 patients,
48.9 %, 95 % (CI), 33.8–62.4 %) than among those who
received HLA-matched HSCT (9 patients, 25.7 %,
95 % (CI), 12.6–41.1 %) (p = 0.033, Fig. 1c). At the time
of analysis, four of the patients who received HLA-matched
HSCT showed signs of extensive cGVHD (cumulative inci-
dence, 11.4 %; 95 % (CI), 3.5–24.5 %), whereas ten of the
patients who received haploidentical HSCT showed such
signs (cumulative incidence, 21.3 %; 95 % (CI), 10.9–34.0 %)
(p = 0.222, Fig. 1d).
The toxicities of the regimens are summarized in
Table 3. There was no hepatic venous occlusive disease
Table 1 Characteristics of patients and donors
Characteristic HLA-matched HSCT Haploidentical HSCT P
(n = 35) (n = 47)
Age, years, median (range) 35(5–52) 35(8–50) 0.679
Males/females, n 22/13 24/23 0.287
WBC count at diagnose × 109, median (range) 45.0(1.4–199.2) 36.3 (1.6–274.4) 0.147
CNS involvement
Yes/no 3/32 6/41 0.548
Disease status at transplantation
CR1 26 37 0.584
>CR1 9 10
BCR-ABL at transplantation
Negative/positive 28/7 37/10 0.888
Average mos. from diagnosis to transplant (range) 9.0(3–47) 7.0(2–19) 0.104
Cycles of prior chemotherapy (range) 5.3(2–22) 4.6(2–13) 0.411
ABO match, no. (%) 0.224
Matched 12 27
Minor mismatched 8 7
Major mismatched 11 9
Major and minor mismatched 4 4





Gao et al. Journal of Hematology & Oncology  (2015) 8:90 Page 4 of 10(HVOD) in either group. The incidences of creatinine
elevation, hemorrhagic cystitis, and heart dysfunction
were very low in both groups. The incidence of CMV
infection was significantly higher among the patients
who received haploidentical HSCT than among those
who received HLA-matched HSCT. Among the patients
who received haploidentical HSCT, three developed
CMV pneumonia and one developed CMV enteritis.
Two of these patients ultimately died of CMV pneumo-
nia. The incidences of other toxicities were not signifi-
cantly different between the two groups.Table 2 Cell yield (cells/kg recipient body weight) given in
average values with minimum and maximum in parentheses
MNC(×108) CD34+ (×106)
G-PBSCs graft
For matched HSCT 9.48(4.27–20.5) 6.48(1.39–31.60)
G-PBSCs graft
For haploidentical HSCT 7.55(2.5–19.71) 4.92(1.03–12.71)
G-BM
For haploidentical HSCT 4.41(1.6–8.46) 1.56(0.54–3.64)Relapse, NRM, OS, and LFS
Five of the transplant patients died before engraftment was
achieved, and 77 achieved molecular CR after transplant-
ation. The patients who received HLA-matched HSCT
were monitored for a median time of 26 months (range
0.2–78 months), and those who received haploidentical
HSCT were monitored for a median time of 31 months
(range 0–81 months). Relapse was defined as molecular re-
lapse, hematological relapse, or extramedullary leukemia re-
lapse. The incidence of relapse was higher among the
patients who received HLA-matched HSCT (14 patients)
than among those who received haploidentical HSCT (9
patients) (cumulative incidence, 44.8 vs. 19.1 %; 95 % (CI),
23.8–63.7 % vs. 9.3–31.6 %) (p = 0.036, Fig. 2a). The
median time until relapse was 4.6 months in the patients
who received HLA-matched HSCT and 7.0 months in
those who received haploidentical HSCT. After recurrence,
three patients in the HLA-matched HSCT group and two
in the haploidentical HSCT group ceased treatment and
died a few weeks later. The other patients who experienced
relapse received imatinib treatment, and several of
them also received chemotherapy, intrathecal chemo-
therapy, DLI, or biotherapy. The remaining six patients
Fig. 1 Cumulative incidence of GVHD. a Acute GVHD, b severe acute GVHD, c chronic GVHD, and d extensive chronic GVHD
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loidentical HSCT group are still alive; three of them
have central nervous system leukemia (CNSL), and
five are BCR-ABL fusion gene-positive. Haploidentical
HSCT was associated with a significantly lower risk of
relapse, as determined by univariate analysis (Table 4)
and confirmed by multivariate analysis (hazard ratio
(HR) 0.413; 95 % (CI), 0.178–0.958) (p = 0.039). How-
ever, >CR1 was a risk factor for recurrence, as deter-
mined by univariate (Table 4) and multivariate analysis
(HR 2.694; 95 % (CI), 1.121–6.475) (p = 0.027). The pa-
tients who had cGVHD appeared to have a lower risk
of relapse by univariate analysis but not by multivariate
analysis. Other factors, such as age, white blood cell
(WBC) count at diagnosis, and the presence of aGVHD,
did not affect the risk of relapse.There was no significant difference in the incidence of
NRM between the patients who received HLA-matched
HSCT (cumulative incidence, six patients, 17.1 %; 95 %
(CI), 6.8–31.4 %) and those who received haploidentical
HSCT (cumulative incidence, ten patients, 21.3 %; 95 %
(CI), 10.9–34.1 %) (p = 0.683, Fig. 2b). The incidences of
NRM were 11.8 and 21.5 % in the BCR-ABL-positive
and BCR-ABL-negative patients, respectively.
The Kaplan-Meier estimate of the 2-year OS of the pa-
tients who received haploidentical HSCT was 63.8 %, which
was similar to that of the patients who received HLA-
matched HSCT (62.6 %) (p = 0.743, Fig. 2c). Univariate ana-
lysis revealed that sex, the WBC count, the presence of
GVHD, and HLA disparity did not significantly influence
the patients’ OS (Table 4). At 2 years, the LFS of the pa-
tients who received haploidentical HSCT was higher than







Transaminase elevation 8(22.9 %) 14(29.8 %) 0.484
Bilirubin elevation 3(8.6 %) 9(19.1 %) 0.180
Gastrointestinal tract
Diarrhea 25(71.4 %) 33(70.2) 0.905
Nausea and vomiting 17(48.6 %) 32(68.1 %) 0.075
Mucositis 13(37.1 %) 21(44.7 %) 0.493
Alimentary tract hemorrhage 2(5.7 %) 6(12.8) 0.287
Urinary tract/kidney
Creatinine elevation 0 1(2.1) 0.385
Hemorrhagic cystitis 1(2.9 %) 1 0.832
Infection
Bacterial infection 23(65.7 %) 32(68.1 %) 0.821
Fungal infection 4(11.4 %) 8(17.0 %) 0.479
CMV infection 5(14.3 %) 18(38.3 %) 0.017
Cardiovascular
Heart dysfunction 1 0 0.244
CMV cytomegalovirus
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(59.5 vs. 45.7 %) (p = 0.118), although this difference was
not statistically significant (Fig. 2d). >CR1 at the time of
transplantation significantly influenced LFS, as determined
by univariate analysis, but this difference was not confirmed
by multivariate analysis (HR 1.895, 95 % (CI), 0.955–3.761)
(p = 0.068). The cumulative 2-year OS rates were 52.9 and
69.2 % in the BCR-ABL-positive and BCR-ABL-negative
patients, respectively (p = 0.325). At 2 years, the LFS rates
were 41.2 % for the BCR-ABL-positive patients and 58.5 %
for the BCR-ABL-negative patients (p = 0.229). Although
there were no significant differences in OS or PFS due to
the limited number of patients included in this study,
the BCR-ABL-negative patients tended to have worse
outcomes.
Discussion
Ph+ ALL is an aggressive disease with a poor prognosis.
Despite an initial favorable response to treatment, the
long-term outcome is unsatisfactory in adults when
TKI/chemotherapy combinations are used without allo-
HSCT. This unfavorable prognosis might justify the use
of alternative conditioning options and higher-risk do-
nors, such as mismatched unrelated donors or haploi-
dentical donors or umbilical cord blood-derived cells. It
is difficult to assess the balance between a greater risk of
treatment-related mortality (TRM) and an increased risk of
relapse. In recent years, considerable progress has been
made in haploidentical HSCT, and the clinical outcomes aswell as the health-related quality of life (HRQoL) of patients
receiving this treatment have been reported to be com-
parable to those of patients receiving HLA-matched
HSCT [14, 15]. Although haploidentical HSCT has be-
come a common treatment in adult patients who lack a
HLA-matched donor, data on its efficacy in Ph+ ALL
are limited. We conducted multicenter analysis of 82
Ph+ ALL patients in southwest China undergoing ei-
ther HLA-matched HSCT or haploidentical HSCT to
examine the effect of haploidentical HSCT on the out-
come of Ph+ ALL.
In recent studies, historical comparisons of patients from
the pre-TKI era have shown that patients who are treated
with TKIs plus chemotherapy have significantly improved
CR rates and prolonged LFS [16–18]. Moreover, the pre-
transplantation use of imatinib improves the outcome of
allo-HSCTand patients’ candidacy of HSCT [19, 20]. Based
on these data, there is now no rationale for omitting TKIs
from induction treatment; accordingly, all of the patients
in our study received imatinib in combination with stand-
ard chemotherapy before transplantation.
Certain studies have found that patients who receive
haploidentical HSCT experience significantly delayed
myeloid and platelet recoveries compared with those re-
ceiving HLA-matched HSCT [14, 21]. However, we
found no difference in engraftment between the patients
who received haploidentical HSCT and those who under-
went HLA-matched HSCT. Differences between our study
and these previous studies include the use of PBMCs plus
BM, the lack of in vitro T cell depletion, and the use of
greater numbers of MNCs and CD34+ cells in our study.
Different studies have obtained different results regarding
the prevalence of GVHD. Luo et al. have reported that
grades II–IV aGVHD and severe aGVHD are significantly
more frequent in patients undergoing haploidentical
HSCT compared with those receiving matched sibling
donor HSCT but that the incidence of cGVHD is not sig-
nificantly affected by donor type [14]. In other studies, the
incidence of GVHD has been reported to be similar be-
tween patients who have received haploidentical HSCT
and those who have undergone matched sibling donor
HSCT [21]. Our results showed that the incidences of
both aGVHD and cGVHD were higher in patients who
received haploidentical HSCTcompared with those who re-
ceived HLA-matched HSCT, but there were no differences
between the two patient groups with regard to the inci-
dences of severe aGVHD and extensive cGVHD. Modern
treatment strategies have reduced complications in patients
receiving haploidentical HSCT, but Wang et al. reported
that the incidence of CMV viremia increased to 64 %
among patients who underwent haploidentical HSCT [22].
In our study, the incidence of CMV viremia in patients
who received haploidentical HSCT was higher than that
in those receiving HLA-matched HSCT. This discrepancy
Fig. 2 a Cumulative incidence of NRM. b Cumulative incidence of relapse. c Kaplan-Meier estimate of LFS. d Kaplan-Meier estimate of OS
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strategy used in haploidentical HSCT [23]. Apart from the
incidence of CMV infection, there were no differences in
the toxicities of the regimens between the two groups, and
no patients in either group experienced HVOD.
The most important finding of this study is that the pa-
tients who received haploidentical HSCT had a significantly
lower incidence of relapse than those who received HLA-
matched HSCT. The lower incidence of relapse among the
patients who received haploidentical HSCT may have been
due to the graft-versus-leukemia (GVL) activity of haploi-
dentical HSCT. We observed a significantly lower rate of
relapse in the patients with cGVHD compared with those
without this disease, in agreement with previously pub-
lished observations [10, 24, 25]. cGVHD has been associ-
ated with a putative GVL effect, and several studies haveshown that it contributes significantly to the eradication of
MRD [10, 24, 25]. The conditioning regimen of haploiden-
tical HSCT is more intensive than that of HLA-matched
HSCT, which is related to the lower rate of relapse in hap-
loidentical HSCT. Previous studies have confirmed a rela-
tionship between chemotherapeutic regimen intensity and
disease recurrence risk. Bredeson et al. [26] compared pa-
tients received FB with those received BuCy, finding that
the relapse rate was higher after FB treatment than after
BuCy treatment. Bachanova et al. [27] have confirmed that
a less intense regimen may not be sufficient to eliminate re-
sidual detectable leukemia.
In our study, the relapse rates were 19.1 % in the pa-
tients who received haploidentical HSCT and 44.8 % in
those who received HLA-matched HSCT. The relapse
rate of the patients who received HLA-matched HSCT
Table 4 Results of univariate analysis of RE, LFS and OS
RE LFS OS
Variable HR(95 % CI) P HR(95 % CI) P HR(95 % CI) P
Age
<40 years 1(Reference) 1(Reference) 1(Reference)
≥40 years 0.752(0.279–2.026) 0.573 0.932(0.454–1.913) 0.849 0.954(0.427–2.314) 0.910
HLA disparity
Identical HSCT 1(Reference) 1(Reference) 1(Reference)
Haploidentical HSCT 0.399(0.173–0.924) 0.032 0.609(0.325–1.143) 0.123 0.889(0.438–1.803) 0.744
Duration from diagnosis to SCT
<180 days 1(Reference) 1(Reference) 1(Reference)
≥180 days 1.775(0.783–4.025) 0.169 1.389(0.740–2.609) 0.306 0.915(0.444–1.886) 0.810
Disease status before transplantation
CR1 1(Reference) 1(Reference) 1(Reference)
>CR1 3.289(1.429–7.569) 0.005 2.279(1.179–4.408) 0.014 1.711(0.804–3.642) 0.164
WBC at diagnosis
<30 × 109/L 1(Reference) 1(Reference) 1(Reference)
≥30 × 109/L 2.272(1–5.165) 0.05 1.842(0.976–3.478) 0.06 1.590(0.778–3.249) 0.204
Acute GVHD
Yes 1(Reference) 1(Reference) 1(Reference)
No 0.562(0.235–1.366) 0.204 0.814(0.427–1.552) 0.532 1.208(0.595–2.451) 0.601
Chronic GVHD
Yes 1(Reference) 1(Reference) 1(Reference)
No 0.5(0.253–0.988) 0.046 0.570(0.241–1.346) 0.2 0.584(0.275–1.242) 0.162
CMV
Positive 1(Reference) 1(Reference) 1(Reference)
Negative 0.511(0.173–1.506) 0.223 1.087(0.55–2.148) 0.81 1.508(0.721–3.155) 1.508
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published reports [5, 18, 28]. This difference might be
due to one or a combination of the following factors.
First, more patients transplanted in >CR1 were included in
our study compared with other studies [5, 28]. Our results
showed that >CR1 at transplantation was associated with
an increased risk of relapse. Chen et al. also suggested that
the remission status at the time of HSCT is significantly
predictive of both LFS and OS [5]. Allo-HSCT in CR1 re-
mains the standard of care at most centers [28]. Second,
we included not only hematological and extramedullary re-
lapse but also molecular relapse in our study. The patients
in our study also did not receive “upfront” imatinib post-
allogeneic HSCT, and imatinib treatment was only initiated
if the BCR-ABL fusion product or extramedullary relapse
was detected. Pfeifer et al. observed molecular recurrence
in 56 % of patients overall [29]. There is insufficient evi-
dence to date indicating that imatinib should be given to
all patients following allogeneic HSCT [5]. Certain centers
have reported that imatinib is poorly tolerated following
myeloablative allogeneic HSCT [5, 17, 30]. A small studyconducted at the University of Minnesota [20] showed a
trend toward an improved outcome in patients treated
with imatinib during the pre- and posttransplantation pe-
riods. Administration of imatinib maintenance therapy
after HSCT has also been suggested to reduce the relapse
rate and improve LFS in Ph+ ALL patients [5]. The only
randomized study of the use of TKIs after allogeneic HSCT
is currently being conducted by the GMALL group [29].
This study showed that prophylactic imatinib treatment
significantly reduced the incidence of molecular relapse
after allogeneic HSCT but that durable PCR negativity
could still be achieved in the majority of posttransplanta-
tion patients with molecular relapse by restarting imatinib
therapy. OS was found to significantly differ between the
two treatment arms. Although haploidentical HSCT re-
duces the risk of disease recurrence, our study found no
difference in either LFS or OS, possibly due to the small
number of included patients and the beneficial effect of
restarting imatinib in most patients.
In conclusion, we found a significant reduction in
the relapse rate in Ph+ ALL patients who have received
Gao et al. Journal of Hematology & Oncology  (2015) 8:90 Page 9 of 10haploidentical HSCT compared with patients who have
undergone HLA-matched HSCT. The incidences of
aGVHD, cGVHD, and CMV viremia were higher in the
patients who received haploidentical HSCT than in those
who received HLA-matched HSCT, but there was no dif-
ference in NRM between these two groups. Although a
well-designed, larger prospective study is needed to define
the role of haploidentical HSCT in disease progression in
patients with Ph+ ALL, our results suggest that haploiden-
tical HSCT is a promising option for Ph+ ALL patients
who lack a suitable HLA-matched donor.
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